Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Erasca (ERAS)
NASDAQ:ERAS
Erasca (ERAS) Stock Price & Analysis
225 Followers
ERAS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.51 - $2.97
Previous Close$2.17
Volume775.86K
Average Volume (3M)2.02M
Market Cap
$563.86M
Enterprise Value$321.12M
Total Cash (Recent Filing)$297.69M
Total Debt (Recent Filing)$54.94M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Aug 08, 2024EPS Estimate
-$0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding173,358,966
10 Day Avg. Volume982,035
30 Day Avg. Volume2,021,464
Standard Deviation0.20
R-Squared0.10
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)1.16
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.82K
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.12
Forecast
1Y Price Target
$5.00Price Target Upside112.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Erasca News
Bulls Say, Bears Say
Bulls Say
Clinical DataERAS-0015 shows no major drug-drug interaction liabilities or major cardiovascular risk concerns.
Financial PerformanceA new $160mn financing extends the cash runway to 1H27.
Pipeline DevelopmentAdding new RAS-targeting assets to the pipeline.
Bears Say
Clinical TrialsERAS-007 failed to show clinical efficacy in its Phase 1/2 trial and, accordingly, the company will cease further development.
Investor ConfidenceThis is the third time the company has done a pipeline reprioritization with its clinical and preclinical portfolios, which leaves investors skeptical on the company’s ability to select the right strategy with the right molecule.
Workforce ReductionThe company announced an 18% workforce reduction.
---
Ownership Overview
21.50% Insiders
4.67% Mutual Funds
21.41% Other Institutional Investors
52.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ERAS FAQ
What was Erasca’s price range in the past 12 months?
Erasca lowest stock price was $1.51 and its highest was $2.97 in the past 12 months.
What is Erasca’s market cap?
Currently, no data Available
When is Erasca’s upcoming earnings report date?
Erasca’s upcoming earnings report date is Aug 08, 2024 which is in 31 days.
How were Erasca’s earnings last quarter?
Erasca released its earnings results on May 09, 2024. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.202 by -$0.028.
Is Erasca overvalued?
According to Wall Street analysts Erasca’s price is currently Undervalued.
Does Erasca pay dividends?
Erasca does not currently pay dividends.
What is Erasca’s EPS estimate?
Erasca’s EPS estimate is -$0.18.
How many shares outstanding does Erasca have?
Erasca has 259,845,460 shares outstanding.
What happened to Erasca’s price movement after its last earnings report?
Erasca reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.202. Following the earnings report the stock price went down -8.837%.
Which hedge fund is a major shareholder of Erasca?
Among the largest hedge funds holding Erasca’s share is Woodline Partners LP. It holds Erasca’s shares valued at 2M.
---
Erasca Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (112.77% Upside)
$5.00 (112.77% Upside)
Hedge Fund Trend
Decreased
By 75.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $181.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.22%
12-Months-Change
Fundamentals
Return on Equity
-37.60%
Trailing 12-Months
Asset Growth
-20.86%
Trailing 12-Months
Company Description
Erasca
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers.
---
ERAS Earnings Call
Q4 2024
0:00 / 0:00
---
ERAS Stock 12 Month Forecast
Average Price Target
$5.00
▲(112.77% Upside)
Technical Analysis
Best Analysts Covering ERAS
1 Year
1 Year Success Rate
3/4 ratings generated profit
1 Year Average Return
+4.47%
reiterated a buy rating 2 months ago
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +4.47% per trade.
---